Hypophosphatemia

This study investigates whether giving phosphate through an IV can reduce the severity of acute pancreatitis in adults. Researchers want to know if low phosphate levels make the disease worse and if replenishing it helps. Participants receive either standard care or IV phosphate …

This study tests whether dipyridamole, a drug usually used for heart conditions, can raise low phosphate levels in kidney transplant recipients. Researchers will give the drug to 90 adult patients when their phosphate drops below normal. The goal is to see if it improves phosphat…

This study tests whether a phosphate supplement in granule form can safely raise low blood phosphate levels in 60 ICU patients. Participants take the granules daily for up to 14 days, with doses adjusted based on how low their phosphate is. Researchers will check blood levels dai…

This study tests a new drug called KK8123 for adults with X-linked hypophosphatemia (XLH), a rare genetic condition that causes low phosphate levels and bone problems. The trial has two parts: first, finding the right dose, then checking safety and how well it works over time. Ab…

This study aims to collect information and bone samples from up to 1,000 people with bone or mineral disorders, such as tumor-induced osteomalacia or familial tumoral calcinosis. Participants receive standard medical evaluations and may provide bone tissue from surgery or a biops…

This study uses a special MRI technique to measure energy molecules (ATP and phosphate) in the leg muscles of people with phosphate diabetes, a condition that causes bone pain and muscle fatigue. By comparing measurements at rest and during exercise, researchers hope to uncover t…

This study looks at how long-term phosphate therapy affects the kidneys, blood vessels, and heart in people with two rare bone disorders: X-linked hypophosphatemia (XLH) and hereditary hypophosphatemic rickets with hypercalciuria (HHRH). Researchers will measure hormone levels an…

XLH is a rare genetic condition that causes low phosphate levels, leading to weak bones and pain. Burosumab is a standard treatment, but the best starting dose is still unclear. This study will review the medical records of 120 children across England to see if a lower dose (unde…